

**FOR IMMEDIATE RELEASE**

October 15, 2013

**Hyundai Hope on Wheels grant received by ApeX Therapeutics  
chief scientific founder**

INDIANAPOLIS – The chief scientific founder of ApeX Therapeutics, a cancer-focused drug discovery and development company with technology licensed from Indiana University Research and Technology Corporation, is among a group of IU School of Medicine faculty to receive a \$250,000 Hyundai Hope Grant for pediatric cancer research.

The grant will support the work of Mark R. Kelley, Ph.D., co-founder of ApeX Therapeutics and associate director of the IU Herman B Wells Center for Pediatric Research, and two School of Medicine colleagues, whose research seeks a new therapeutic strategy to treat T-cell leukemia, namely for children with relapsed acute lymphoblastic leukemia or ALL – the most common type of leukemia in children.

Because childhood leukemia that has relapsed or is resistant to, or does not respond to, treatment is often associated with a grave prognosis, there is keen interest in research that translates into effective therapeutic strategies benefiting this population of approximately 6,000 children per year.

ApeX Therapeutics, funded in part by the Innovate Indiana Fund, Pearl Street Venture Fund and BioCrossroads, also recently received a Phase I, Small Business Innovation Research grant for \$240,332 from the National Cancer Institute at the National Institutes of Health to develop an oral or injectable form of medicine to more effectively treat leukemia and other cancerous tumors in children.

ApeX Therapeutics is steadily progressing towards its next milestone: a pre-investigational new drug meeting with the U.S. Food and Drug Administration to establish a safe and efficient path to first-in-human trials in several different types of leukemia.